Pitavastatin: focus on safety and drug interactions
Pitavastatin is a drug from the group of HMG-CoA reductase inhibitors, which has good lipid-lowering efficacy and has no significant effect on the risk of diabetes mellitus. This drug is non significantly metabolized by the P450 cytochrome system, which minimizes the risk of possible drug-drug inter...
Enregistré dans:
Auteurs principaux: | Larisa O. Minushkina, Dmitry A. Zateyshchikov |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Concilium Medicum
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/64f2f979611d4d8f8eeeb8ca730ad066 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Statins and diabetes: focus on pitavastatin
par: Soreiia A. Urazgildeeva
Publié: (2020) -
Obituary: Academician of the Russian Academy of Sciences, Professor Rafael G. Oganov 09.12.1937–24.09.2020. Professor Anatoliy N. Britov 15.01.1934–03.12.2020
par: Editorial bord Cardiosomatics
Publié: (2021) -
American physician Samuel A. Levine and his contribution into the cardiac rehabilitation
par: David M. Aronov
Publié: (2021) -
Human serum metabolomic analysis reveals progression for high blood pressure in type 2 diabetes mellitus
par: Li Li, et autres
Publié: (2021) -
Quality gaps in screening and monitoring for postoperative hyperglycemia in a Canadian hospital: a retrospective cohort study
par: Anna Cameron, et autres
Publié: (2021)